Literature DB >> 9257866

Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines.

S Sozzani1, W Luini, A Borsatti, N Polentarutti, D Zhou, L Piemonti, G D'Amico, C A Power, T N Wells, M Gobbi, P Allavena, A Mantovani.   

Abstract

Dendritic cells (DC) are migratory cells that exhibit complex trafficking properties in vivo. The present study was designed to characterize receptor expression and responsiveness to chemoattractants of human DC obtained from PBMC by culture with granulocyte/macrophage-CSF and IL-13. DC expressed appreciable levels of the CCR1, CCR2, and CCR5 receptors for the CC chemokines and the chemokine receptors CXCR1, CXCR2, and CXCR4. DC increased intracellular free calcium and migrated in response to the CC chemokines MCP-3, MCP-4, RANTES, MIP-1alpha, MIP-1beta, and MIP-5/HCC2 and the CXC chemokine SDF-1. In contrast, the CC chemokines MCP-1 and eotaxin had little or no activity in the concentration range tested (up to 1 microg/ml). IL-8 and Gro-beta (CXC) and lymphotactin (C chemokines) were also inactive. DC did not respond to 5-HETE, whereas platelet-activating factor was an active agonist. Selected chemokines active on DC in terms of migration and calcium fluxes were examined for their capacity to modulate endocytosis and Ag presentation. Under conditions in which TNF-alpha was active, MCP-1, MCP-3, MIP-1alpha, and RANTES did not affect these two responses. Thus, among hemopoietic elements, DC respond to a unique set of CC and CXC chemokines, and their responsiveness is restricted to migration with no effect on Ag capture and presentation. Chemokines may play a role in the trafficking of DC under resting or stimulated conditions. Chemokine receptors expressed in DC are likely to underlie HIV infection of this cell type.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9257866

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  77 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Interleukin 12 and innate molecules for enhanced mucosal immunity.

Authors:  P N Boyaka; J W Lillard; J McGhee
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

3.  CXC chemokine receptor 4 expression and stromal cell-derived factor-1alpha-induced chemotaxis in CD4+ T lymphocytes are regulated by interleukin-4 and interleukin-10.

Authors:  T Jinquan; S Quan; H H Jacobi; H O Madsen; C Glue; P S Skov; H J Malling; L K Poulsen
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

Review 4.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

Review 5.  Dendritic cells: immune saviors or Achilles' heel?

Authors:  C W Cutler; R Jotwani; B Pulendran
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 7.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 8.  Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation.

Authors:  Junxi Wu; Jun Li; Nannan Zhang; Cuihua Zhang
Journal:  Basic Res Cardiol       Date:  2011-03-23       Impact factor: 17.165

9.  Chemokines and their receptors in intracerebral hemorrhage.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Transl Stroke Res       Date:  2012-04-03       Impact factor: 6.829

10.  Cross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1.

Authors:  Filip Bednar; Changcheng Song; Giuseppe Bardi; William Cornwell; Thomas J Rogers
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.